[Oral contraceptives and diabetes].
Some remarks are presented on the contraceptive treatment of diabetic females with emphasis on the relationship between progestins and estrogenic progestins and the metabolism of carbohydrates and fats, haemostasis and arterial hypertension. Indications for the contraceptive treatment of insulin dependent and non-insulin dependent diabetics and subjects exposed to diabetic risk are supplied.
D003276:Contraceptives, Oral / Q000009:adverse effects / Q000378:metabolism*; D003920:Diabetes Mellitus / Q000097:blood / Q000378:metabolism*; D003922:Diabetes Mellitus, Type 1 / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D045166:Estradiol Congeners / Q000009:adverse effects / Q000378:metabolism; D005260:Female; D005947:Glucose / Q000378:metabolism*; D005951:Glucose Tolerance Test; D006487:Hemostasis / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D050356:Lipid Metabolism; D045167:Progesterone Congeners / Q000009:adverse effects / Q000378:metabolism; D012306:Risk; D013997:Time Factors
D003276:Contraceptives, Oral; D045166:Estradiol Congeners; D045167:Progesterone Congeners; D005947:Glucose
Contraccettivi orali e diabete.